Advertisement

Safety of Insomnia Pharmacotherapy

  • Timothy Roehrs
    Correspondence
    Corresponding author. Sleep Disorders and Research Center, Henry Ford Hospital, 2799 West Grand Boulevard, CFP-3, Detroit, MI 48202.
    Affiliations
    Sleep Disorders and Research Center, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA

    Department of Psychiatry and Behavioral Neuroscience, School of Medicine, Wayne State University, 2751 E Jefferson, Detroit, MI 48207, USA
    Search for articles by this author
  • Thomas Roth
    Affiliations
    Sleep Disorders and Research Center, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA

    Department of Psychiatry and Behavioral Neuroscience, School of Medicine, Wayne State University, 2751 E Jefferson, Detroit, MI 48207, USA
    Search for articles by this author
      As in any disease, the therapeutic benefit of pharmacotherapy to the patient who has insomnia is judged against the safety of that treatment. This article discusses the safety of pharmacotherapy for insomnia.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Sleep Medicine Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Zammit G.K.
        • Weiner J.
        • Damato N.
        • et al.
        Quality of life in people with insomnia.
        Sleep. 1999; 22: S379-S385
        • Katz D.A.
        • McHorney C.A.
        The relationship between insomnia and health-related quality of life in patients with chronic illness.
        J Fam Pract. 2002; 51: 229-235
        • Simon G.E.
        • Von Korff M.
        Prevalence, burden, and treatment of insomnia in primary care.
        Am J Psychiatry. 1997; 154: 1417-1423
        • Leger D.
        • Guilleminault C.
        • Bader G.
        • et al.
        Medical and socio-professional impact of insomnia.
        Sleep. 2002; 25: 625-629
        • Avidan A.Y.
        • Fries B.E.
        • James M.L.
        • et al.
        Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes.
        J Am Geriatr Soc. 2005; 53: 955-962
        • Breslau N.
        • Roth T.
        • Rosenthal L.
        • et al.
        Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults.
        Biol Psychiatry. 1996; 39: 411-418
        • Chang P.P.
        • Ford D.E.
        • Mead L.A.
        • et al.
        Insomnia in young men and subsequent depression. The Johns Hopkins Precursor Study.
        Am J Epidemiol. 1997; 146: 105-114
        • Perlis M.L.
        • Giles D.E.
        • Buysse D.J.
        Self-reported sleep disturbance as a prodromal symptom in recurrent depression.
        J Affect Disord. 1997; 42: 209-212
        • Fava M.
        • McCall W.V.
        • Krystal A.
        • et al.
        Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
        Biol Psychiatry. 2006; 59: 1052-1060
        • Affleck G.
        • Urrows S.
        • Tennen H.
        • et al.
        Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia.
        Pain. 1996; 68: 363-368
        • Walsh J.K.
        • Muehlbach M.J.
        • Lauter S.A.
        • et al.
        Effect of triazolam on sleep, daytime sleepiness and morning stiffness in patients with rheumatoid arthritis.
        J Rheumatol. 1996; 23: 245-252
        • Drewes A.M.
        • Bjerregard K.
        • Jorgensen T.
        • et al.
        Zopiclone as night medication in rheumatoid arthritis.
        Scan J Rheumatol. 1998; 27: 180-187
      1. Schnitzer T, Rubens R, Price J, et al. The effect of eszopiclone 3 mg compared with placebo in patients with rheumatoid arthritis and co-existing insomnia [abstract]. Poster presented at Sleep 2006. Salt Lake City, UT, June 18–22, 2006.

        • Roehrs T.
        • Hyde M.
        • Blaisdell B.
        • et al.
        Sleep loss and REM sleep loss are hyperalgesic.
        Sleep. 2006; 29: 145-151
        • Jefferson C.D.
        • Drake C.l.
        • Scofield H.M.
        • et al.
        Sleep hygiene practices in a population-based sample of insomniacs.
        Sleep. 2005; 28: 611-615
        • Ancoli-Israel S.
        • Roth T.
        Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I.
        Sleep. 1999; 22: S347-S353
        • The Gallup Organization
        Sleep in America.
        Gallup Organization, Princeton (NJ)1995 (p. 1–78)
        • Johnson E.O.
        • Roehrs T.
        • Roth T.
        • et al.
        Epidemiology of alcohol and medication as aids to sleep in early adulthood.
        Sleep. 1998; 21: 178-186
        • Roehrs T.
        • Hollebeek E.
        • Drake C.
        • et al.
        Substance use for insomnia in metropolitan Detroit.
        J Psychosom Res. 2002; 53: 571-576
        • Richardson G.
        • Roehrs T.
        • Rosenthal L.
        • et al.
        Tolerance to daytime sedative effects of H1 antihistamines.
        J Clin Psychopharmacol. 2002; 22: 511-515
        • Roehrs T.
        • Papineau K.
        • Rosenthal L.
        • et al.
        Ethanol as a hypnotic in insomniacs: self administration and effects of sleep and mood.
        Neuropsychopharmacology. 1999; 20: 279-286
        • Roehrs T.
        • Blaisdell B.
        • Cruz N.
        • et al.
        Tolerance to hypnotic effects of ethanol in insomnias.
        Sleep. 2004; 27 ([abstract]): A52
        • Roehrs T.A.
        • Blaisdell B.
        • Richardson G.S.
        • et al.
        Insomnia as a path to alcoholism: dose escalation.
        Sleep. 2003; 26 ([abstract]): A307
        • Roth T.
        • Roehrs T.A.
        • Vogel G.W.
        • et al.
        Evaluation of hypnotic medications.
        in: Prien R.F. Robinson D.S. Clinical evaluation of psychotropic drugs: principles and guidelines. Raven Press, New York1995: 579-592
        • Rush C.R.
        • Griffiths R.R.
        Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers.
        J Clin Psychopharmacol. 1996; 16: 146-157
        • Carskadon M.A.
        • Seidel W.F.
        • Greenblatt D.J.
        • et al.
        Daytime carryover of triazolam and flurazepam in elderly insomniacs.
        Sleep. 1982; 5: 361-371
        • Danjou P.
        • Fruncillo P.R.
        • Worthington P.
        • et al.
        A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening.
        Br J Clin Pharmacol. 1999; 48: 367-374
        • Roehrs T.
        • Merlotti L.
        • Zorick F.
        • et al.
        Sedative, memory and performance effects of hypnotics.
        Psychopharmacology (Berl). 1994; 116: 130-134
        • Roehrs T.
        • Zorick F.
        • Sicklesteel J.
        • et al.
        Effects of hypnotics on memory.
        J Clin Psychopharmacol. 1983; 3: 310-313
        • Curran H.V.
        • Birch B.
        Differentiating the sedative, psychomotor and amnesic effects of benzodiazepines: a study with midazolam and the benzodiazepine antagonist, flumazenil.
        Psychopharmacology (Berl). 1991; 103: 519-523
        • Green J.F.
        • McElholm A.
        • King D.J.
        A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam.
        Psychopharmacology (Berl). 1996; 128: 67-73
        • Mohler H.
        • Crestani F.
        • Rudolph
        GABA-A receptor subtypes: a new pharmacology.
        Curr Opinion Pharmacol. 2001; 1: 22-25
        • Paterniti S.
        • Dufouil C.
        • Alperovitch A.
        Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study.
        J Clin Psychopharmacol. 2002; 22: 285-293
        • Allard J.
        • Artero S.
        • Ritchie K.
        Consumption of psychotropic medication in the elderly: a re-evaluation of its effect on cognitive performance.
        Int J Geriatr Psychiatry. 2003; 18: 874-878
        • McAndrews M.P.
        • Weiss R.T.
        • Sandor P.
        • et al.
        Cognitive effects of long-term benzodiazepine use in older adults.
        Hum Psychopharmacol. 2003; 18: 51-57
        • Roehrs T.A.
        • Vogel G.
        • Roth T.
        Rebound insomnia: its determinants and significance.
        Am J Med. 1990; 88: 43S-46S
      2. Krystal A, Walsh J, Roth T, et al. Evaluation of the efficacy and safety of eszopiclone over six months of treatment in patients with insomnia [abstract]. Poster presented at Sleep 2006. Salt Lake City, UT, June 18–22, 2006.

        • Roehrs T.
        • Merlotti L.
        • Zorick F.
        • et al.
        Rebound insomnia and hypnotic self administration.
        Psychopharmacology (Berl). 1992; 107: 480-484
        • Woods J.H.
        • Winger G.
        Current benzodiazepine issues.
        Psychopharmacology (Berl). 1995; 118: 107-115
        • Mellinger G.D.
        • Balter M.B.
        • Uhlenhuth E.H.
        Insomnia and its treatment.
        Arch Gen Psychiatry. 1985; 42: 225-232
        • Roehrs T.
        • Hollebeek E.
        • Drake C.
        • et al.
        Substance use for insomnia in Metropolitan Detroit.
        J Psychosom Res. 2002; 53: 571-576
        • Krystal A.D.
        • Walsh J.K.
        • Laska E.
        • et al.
        Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.
        Sleep. 2003; 26: 793-799
        • Roehrs T.
        • Bonahoom A.
        • Pedrosi B.
        • et al.
        Disturbed sleep predicts hypnotic self administration.
        Sleep Med. 2002; 3: 61-66
        • Roehrs T.
        • Pedrosi B.
        • Rosenthal L.
        • et al.
        Hypnotic self administration and dose escalation.
        Psychopharmacology (Berl). 1996; 127: 150-154
        • Roehrs T.
        • Bonahoom A.
        • Pedrosi B.
        • et al.
        Nighttime versus daytime hypnotic self-administration.
        Psychopharmacology (Berl). 2002; 161: 137-142
        • Griffiths R.R.
        • Johnson M.W.
        Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds.
        J Clin Psychiatry. 2005; 66: 31-41
        • Mendelson W.B.
        The use of sedative/hypnotic medication and its correlation with falling down in the hospital.
        Sleep. 1996; 19: 698-701
        • Ensrud K.E.
        • Blackwell T.L.
        • Mangione C.M.
        • et al.
        Central nervous system-active medications and risk for falls in older women.
        J Am Geriatr Soc. 2002; 50: 1629-1637
        • Kallin K.
        • Lundin-Olsson L.
        • Jensen J.
        • et al.
        Predisposing and precipitating factors for falls among older people in residential care.
        Public Health. 2002; 116: 263-271
        • Thapa P.B.
        • Gideon P.
        • Cost T.W.
        • et al.
        Antidepressants and the risk of falls among nursing home residents.
        N Engl J Med. 1998; 339: 875-882
        • Brassington G.S.
        • King A.C.
        • Bliwise D.L.
        Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64–99 years.
        J Am Geriatr Soc. 2000; 48: 1234-1240
        • Shader R.I.
        • Greenblatt D.J.
        Triazolam and anterograde amnesia: all is not well in the z-zone.
        J Clin Psychopharmcol. 1983; 3: 273
        • Morris H.H.
        • Estes M.L.
        Traveler's amnesia. Transient global amnesia secondary to triazolam.
        JAMA. 1987; 258: 945-946
        • Yang W.
        • Dollear M.
        • Muthukrishnan S.R.
        One rare side effect of zolpidem – sleepwalking: a case report.
        Arch Phys Med Rehabil. 2005; 86: 1265-1266
        • Liskow B.
        • Pikalov A.
        Zaleplon overdose associated with sleepwalking and complex behavior.
        J Am Acad Child Adolesc Psychiatry. 2004; 43: 927-928
        • Lange C.L.
        Medication-associated somnambulism.
        J Am Acad Child Adolesc Psychiatry. 2005; 44: 211-212
        • Paquet V.
        • Strul J.
        • Servais L.
        • et al.
        Sleep-related eating disorder induced by olanzapine.
        J Clin Psychiatry. 2002; 63: 7
        • Lu M.L.
        • Shen W.W.
        Sleep-related eating disorder induced by risperidone.
        J Clin Psychiatry. 2004; 65: 273-274
        • Morgenthaler T.I.
        • Silber M.H.
        Amnestic sleep-related eating disorder associated with zolpidem.
        Sleep Med. 2002; 3: 323-327
        • Schenk C.H.
        • Mahowald M.W.
        Review of nocturnal sleep-related eating disorders.
        Int J Eat Disord. 1994; 15: 343-356
        • Vetrugno R.
        • Manconi M.
        • Strembi L.F.
        • et al.
        Nocturnal eating: sleep related eating disorder or nocturnal eating syndrome? A videopolysomnographic study.
        Sleep. 2006; 29: 957-966
        • Menkes D.B.
        Triazolam-induced nocturnal bingeing with amnesia.
        Aust N Z J Psychaitry. 1992; 26: 320-321
        • Lauerma H.
        Nocturnal wandering caused by restless legs and short-acting benzodiazepines.
        Acta Psychiatr Scand. 1991; 83: 492-493
        • Mendelson W.B.
        • Thompson C.
        • Franko T.
        Adverse reactions to sedative hypnotics: three years' experience.
        Sleep. 1996; 19: 702-706
        • Kato K.
        • Hirai K.
        • Nichiyama K.
        • et al.
        Neurochemical properties of ramelteon (TAK-375), a selective MT1 / MT2 receptor agonist.
        Neuropharmacology. 2005; 48: 301-310
        • Karin A.
        • Tolbert D.
        • Cao C.
        Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia.
        J Clin Pharmacol. 2006; 46: 140-148
        • Compton-McBride S.
        • Schweitzer
        • Walsh J.K.
        Most commonly used drugs to treat insomnia in 2002.
        Sleep. 2004; 27 ([abstract]): A255
        • Mendelson W.B.
        A review of the evidence for the efficacy and safety of trazodone in insomnia.
        J Clin Psychiatry. 2005; 66: 469-476
        • Walsh J.K.
        • Erman M.
        • Erwin C.W.
        • et al.
        Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia.
        Hum Psychopharmacol. 1998; 13: 191-198
        • Thompson J.W.
        • Ware M.R.
        • Blashfield R.K.
        Psychotropic medication and priapism: a comprehensive review.
        J Clin Psychiatry. 1990; 51: 430-433
        • Flores B.H.
        • Schatzberg A.F.
        Mirtazepine.
        in: Schatzberg A. Nemeroff C. The American Psychiatric Publishing textbook of psychopharmacology. American Psychiatric Publishing, Inc., Washington (DC)2004: 341-347
        • National Institutes of Health State of the Science Conference
        Manifestations and management of chronic insomnia in adults. June 13–15, 2005.
        Sleep. 2005; 28: 1049-1057
        • Bunney W.E.
        • Azarnoff D.L.
        • Brown B.W.
        • et al.
        Report of the Institute of Medicine Committee on the efficacy and safety of halcyon.
        Arch Gen Psychiatry. 1999; 56: 349-352